This summit includes three parallel conferences focused on both the research, and business perspectives in oncology.
This summit will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials working to identify and exploit advances in the field of oncology in order to deliver products with a meaningful clinical impact. In addition, industry leaders from big pharma and various biotech/pharmaceutical companies, including business/corporate development executives, licensing executives, global alliance, and venture capitalists, will all be present to explore potential collaborations and learn about relevant issues in oncology.
Focus areas include cancer diagnostics, cancer immunotherapy, as well as partnering and deal-making in oncology. Discussion topics include emerging targets, therapeutic strategies, next generation sequencing in cancer diagnosis, progress in cancer immunotherapy, combination strategies in immuno-oncology, advancements in technology, as well as business development trends, markets, partnership opportunities, and access to capital market.
Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer!
Session Topics:
Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for the Future
Complementary & Companion Diagnostics in Oncology
I. Next Generation Sequencing in Cancer Diagnosis
II. Liquid Biopsy for Cancer Detection & Monitoring
III. Genomic Biomarkers in Immunotherapy
IV. Case Studies for Development & Commercialization
Cancer Immunotherapy
I. Immunomodulatory Antibodies
II. Precision Medicine and Biomarkers for Immunotherapy
III. Novel Druggable Targets for Immunotherapy
IV. Combination Immunotherapy
Oncology Partnering & Deal-Making
I. What sells in Oncology – New Targets, Models, Assays, etc.
II. Industry Partnering with Academic Groups & CROs to Advance Research
III. Oncology Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities